Recent studies have highlighted a concerning trend: people recovering from COVID-19 may face an elevated risk of developing diabetes. This association appears to stem from two main factors. Firstly, COVID-19 may directly damage pancreatic beta cells, which are crucial for insulin production. This impairment reduces the pancreas’s ability to generate sufficient insulin, leading to uncontrolled blood sugar levels. Secondly, as the virus replicates in the pancreas, it can also harm cells surrounding the beta cells, further disrupting proper insulin release.
Interestingly, researchers have observed similar hyperglycemia risks in other severe lung dysfunction cases, such as ARDS, whether related to COVID-19 or other causes like severe influenza or bacterial pneumonia. However, in non-COVID-19 cases, hyperglycemia is primarily attributed to different factors.
Acute stressors, including pregnancy, steroids, or inflammation from cytokine activation (common in COVID-19 patients), can induce hyperglycemia in individuals without a prior diabetes diagnosis. These stressors act as a “treadmill test for the pancreas,” revealing underlying vulnerabilities. A pancreas at risk of Type 2 diabetes might thus fail under such stress.
Harvard Medical School researchers found that many COVID-19 patients newly diagnosed with diabetes during hospitalization might experience a temporary form of the disease. This form is related to the acute stress of the viral infection, and blood sugar levels may normalize post-discharge. However, there’s also an increased risk of developing Type 1 diabetes post-COVID-19 infection, as indicated by a study examining over 27 million people in the United States.
The pandemic has also posed challenges for individuals with pre-existing diabetes. The use of dexamethasone, a treatment for COVID-19, can dangerously elevate blood sugar levels. As a result, diabetic patients with COVID-19 have required significantly more insulin, leading to an increase in complications.
Furthermore, a study published in Diabetologia reviewed data on 8.8 million people across Germany, finding that individuals recovering from COVID-19 have a substantially higher risk of developing type 2 diabetes. This was based on data collected from March 2020 through July 2021, during which 35,865 people were diagnosed with COVID-19.
For more detailed information, visit Harvard Health, Weill Cornell News, Wexner Medical, Harvard Medical School, Northeastern News, and Johns Hopkins Public Health.
The evolving understanding of COVID-19’s impact on metabolic health underscores the importance of continuous research and patient monitoring post-infection. These insights are crucial for developing targeted interventions to mitigate the risk of diabetes following COVID-19.